Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Medibio

DB:BPN
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BPN
DB
A$8M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Medibio has significant price volatility in the past 3 months.
BPN Share Price and Events
7 Day Returns
0%
DB:BPN
16.8%
DE Healthcare Services
2.1%
DE Market
1 Year Returns
-87.5%
DB:BPN
15.8%
DE Healthcare Services
-16.6%
DE Market
BPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medibio (BPN) 0% 0% 0% -87.5% - -
DE Healthcare Services 16.8% 4.4% -1.9% 15.8% 50.3% 117%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • BPN underperformed the Healthcare Services industry which returned 15.8% over the past year.
  • BPN underperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
BPN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Medibio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medibio. This is due to cash flow or dividend data being unavailable. The share price is €0.0005.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medibio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medibio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$-0.01
ASX:MEB Share Price ** ASX (2020-04-07) in AUD A$0.01
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.51x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medibio.

DB:BPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MEB Share Price ÷ EPS (both in AUD)

= 0.01 ÷ -0.01

-0.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medibio is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Medibio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Medibio's expected growth come at a high price?
Raw Data
DB:BPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.68x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medibio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medibio's assets?
Raw Data
DB:BPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$0.01
ASX:MEB Share Price * ASX (2020-04-07) in AUD A$0.01
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.82x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:BPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MEB Share Price ÷ Book Value per Share (both in AUD)

= 0.01 ÷ 0.01

0.6x

* Primary Listing of Medibio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medibio is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Medibio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Medibio has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medibio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medibio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.9%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medibio expected to grow at an attractive rate?
  • Unable to compare Medibio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medibio's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Medibio's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:BPN Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 26.9%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BPN Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:BPN Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -5 -5
2019-09-30 3 -6 -6
2019-06-30 4 -7 -7
2019-03-31 3 -10 -11
2018-12-31 3 -13 -15
2018-09-30 3 -13 -15
2018-06-30 2 -12 -16
2018-03-31 3 -10 -15
2017-12-31 3 -8 -13
2017-09-30 3 -7 -11
2017-06-30 3 -5 -10
2017-03-31 3 -4 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medibio is high growth as no earnings estimate data is available.
  • Unable to determine if Medibio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medibio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BPN Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:BPN Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 -0.01
2019-09-30 -0.02
2019-06-30 -0.03
2019-03-31 -0.05
2018-12-31 -0.07
2018-09-30 -0.08
2018-06-30 -0.09
2018-03-31 -0.08
2017-12-31 -0.08
2017-09-30 -0.08
2017-06-30 -0.07
2017-03-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medibio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Medibio's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Medibio's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Medibio's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medibio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medibio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medibio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medibio's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medibio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medibio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medibio's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Medibio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medibio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BPN Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.47 -4.99 2.22 0.63
2019-09-30 2.79 -5.79 3.38 0.51
2019-06-30 4.10 -6.59 4.54 0.39
2019-03-31 3.47 -10.60 6.14 1.96
2018-12-31 2.83 -14.62 7.75 3.39
2018-09-30 2.65 -15.46 7.19 3.32
2018-06-30 2.46 -16.30 6.62 3.26
2018-03-31 2.78 -14.63 5.15 3.79
2017-12-31 3.09 -12.97 3.69 4.32
2017-09-30 3.11 -11.38 2.82 4.32
2017-06-30 3.12 -9.79 1.96 4.32
2017-03-31 3.36 -8.54 1.71 3.03
2016-12-31 3.60 -7.29 1.47 1.75
2016-09-30 2.68 -6.55 1.14 1.80
2016-06-30 1.76 -5.82 0.81 1.85
2016-03-31 1.62 -6.38 0.65 1.09
2015-12-31 1.49 -6.94 0.49 0.32
2015-09-30 0.87 -7.43 0.49 0.26
2015-06-30 0.26 -7.92 0.49 0.21
2015-03-31 -0.11 -5.20 0.35 0.11
2014-12-31 -0.47 -2.48 0.20 0.02
2014-09-30 -0.23 -1.45 0.17 0.02
2014-06-30 -0.43 0.14 0.02
2014-03-31 0.23 -0.37 0.16 0.01
2013-12-31 0.46 -0.32 0.19 0.00
2013-09-30 0.24 -0.71 0.22 0.00
2013-06-30 0.02 -1.10 0.26 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medibio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medibio has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medibio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medibio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medibio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medibio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medibio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medibio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medibio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medibio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Medibio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medibio Company Filings, last reported 3 months ago.

DB:BPN Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 13.38 0.00 2.20
2019-09-30 13.38 0.00 2.20
2019-06-30 8.60 2.75 1.33
2019-03-31 8.60 2.75 1.33
2018-12-31 10.01 0.67 2.15
2018-09-30 10.01 0.67 2.15
2018-06-30 13.99 0.12 6.12
2018-03-31 13.99 0.12 6.12
2017-12-31 23.77 0.12 15.12
2017-09-30 23.77 0.12 15.12
2017-06-30 13.31 0.13 5.01
2017-03-31 13.31 0.13 5.01
2016-12-31 20.01 3.44 12.76
2016-09-30 20.01 3.44 12.76
2016-06-30 8.49 3.69 1.04
2016-03-31 8.49 3.69 1.04
2015-12-31 11.17 3.82 1.89
2015-09-30 11.17 3.82 1.89
2015-06-30 9.11 3.69 0.94
2015-03-31 9.11 3.69 0.94
2014-12-31 1.68 2.56 0.30
2014-09-30 1.68 2.56 0.30
2014-06-30 2.71 1.93 0.10
2014-03-31 2.71 1.93 0.10
2013-12-31 2.63 1.50 0.24
2013-09-30 2.63 1.50 0.24
2013-06-30 2.54 2.42 0.18
  • Medibio has no debt.
  • Medibio has no debt compared to 5 years ago when it was 145.7%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medibio has less than a year of cash runway based on current free cash flow.
  • Medibio has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.6% each year.
X
Financial health checks
We assess Medibio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medibio has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medibio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medibio dividends.
If you bought €2,000 of Medibio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medibio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medibio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BPN Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medibio has not reported any payouts.
  • Unable to verify if Medibio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medibio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medibio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medibio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medibio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medibio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medibio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Claude Solitario
COMPENSATION A$18,630
TENURE AS CEO 0.3 years
CEO Bio

Mr. Claude Solitario is the Managing Director of Medibio Limited since January 9, 2020. He has been Director at Medibio Ltd. since December 31, 2018. He served as the Head of E-Health Business at Medibio Limited (formerly BioProspect Ltd.) from September 2014 to March 17, 2016 and also served as its Head of Consumer Division. Mr. Solitario Co- Founded Invatec Health Pty Ltd (Invatec) in 2005. He has been instrumental in the growth of Invatec since its inception. He has years of commercial and research experience and has a deep understanding of the development and commercialisation of intellectual property. He served as Company Secretary of Safe Effect Technologies Ltd. He served as an Executive Director of Medibio Limited (formerly, BioProspect Ltd.) from April 29, 2014 to September 8, 2014. He serves as Director of Invatec Health Pty Ltd. In May 2018, Medibio received CE (Conformité Européenne) Marking certification for its first release technology product and platform. He is Partner at Cove Capital Pty Ltd. Mr. Solitario is an experienced financial executive having commenced his career at Arthur Young (now Ernst & Young), Chartered Accountants in 1982. His experience since his early days as a Chartered Accountant spans across many industries having acted in senior management, company secretarial and directorship roles in organisations involved in environmental technology, automotive technology, telecommunications, film and television production, winemaking, primary production and in recent years biotechnology and medical technology. Mr. Solitario years of considerable experience in the development of new and emerging technology, with a deep understanding of licensing and commercialisation of intellectual property. He has raised over $150M in capital from private, public and government institutions, predominantly for the development of intellectual property.

CEO Compensation
  • Insufficient data for Claude to compare compensation growth.
  • Claude's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Medibio management team in years:

1.6
Average Tenure
  • The average tenure for the Medibio management team is less than 2 years, this suggests a new team.
Management Team

Claude Solitario

TITLE
MD & Director
COMPENSATION
A$19K
TENURE
0.3 yrs

Melanie Jaye Leydin

TITLE
Joint Company Secretary & Director
COMPENSATION
A$148K
AGE
46
TENURE
1.8 yrs

Renee Stanton-Horne

TITLE
Operations & Account Manager
TENURE
0.3 yrs

Stephanie Ottens

TITLE
Investor Relations Director

Josh Purdy

TITLE
Public Relations Director

Michael Player

TITLE
Head of Research
TENURE
4.1 yrs

Matt Flax

TITLE
Head of Algorithm Development Team
TENURE
4.1 yrs

Archie Defillo

TITLE
Chief Medical Officer & Member of the Scientific Advisory Board

Jennifer Solitario

TITLE
Senior Vice President of Corporate Health
TENURE
1.6 yrs

Massimiliano Grassi

TITLE
Head of Artificial Intelligence
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the Medibio board of directors in years:

1.7
Average Tenure
  • The average tenure for the Medibio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Claude Solitario

TITLE
MD & Director
COMPENSATION
A$19K
TENURE
1.3 yrs

Melanie Jaye Leydin

TITLE
Joint Company Secretary & Director
COMPENSATION
A$148K
AGE
46
TENURE
1.2 yrs

Archie Defillo

TITLE
Chief Medical Officer & Member of the Scientific Advisory Board
TENURE
2 yrs

Peter Carlisle

TITLE
Chairman of Growth & Advocacy Advisory Board and Non-Executive & Lead Independent Director
COMPENSATION
A$73K
TENURE
0.7 yrs

Michael Phelps

TITLE
Member of Growth & Advocacy Advisory Board
COMPENSATION
A$62K
TENURE
0.7 yrs

Patrick Kennedy

TITLE
Member of Growth & Advocacy Advisory Board
COMPENSATION
A$64K
TENURE
0.7 yrs

Martin Chapman

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Joel Ehrenkranz

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Mark Frye

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Lawrence Hunter

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Sep 19 Buy FIL Limited Company 29. Aug 19 29. Aug 19 51,300,000 €0.01 €312,140
29. Aug 19 Buy Marble Bar Asset Management LLP Company 28. Aug 19 28. Aug 19 25,000,000 €0.01 €152,201
X
Management checks
We assess Medibio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medibio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, and commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. Medibio Limited has a research agreement with the Department of Biomedical Sciences of Humanitas University for the development of mental health software products. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was founded in 1998 and is headquartered in Savage, Minnesota.

Details
Name: Medibio Limited
BPN
Exchange: DB
Founded: 1998
A$4,523,128
995,130,039
Website: http://www.medibio.com.au
Address: Medibio Limited
8696 Eagle Creek Circle,
Savage,
Minnesota, 55378,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MEB Ordinary Shares Australian Securities Exchange AU AUD 29. Jan 2001
OTCPK MDBI.F Ordinary Shares Pink Sheets LLC US USD 29. Jan 2001
DB BPN Ordinary Shares Deutsche Boerse AG DE EUR 29. Jan 2001
CHIA MEB Ordinary Shares Chi-X Australia AU AUD 29. Jan 2001
Number of employees
Current staff
Staff numbers
0
Medibio employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 02:00
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2018/08/29
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.